This Week in The Roadhouse Pharmacy
THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.
Clinuvel Pharmaceuticals scores US orphan-drug designation
Clinuvel Pharmaceuticals (ASX: CUV) has announced that afamelanotide, the active ingredient in the company’s proprietary drug SCENESSE®, has received orphan-drug designation from the US Food and Drug Administration (FDA) for the rare Hailey-Hailey Disease (HHD, also known as familial benign chronic pemphigus). READ MORE…
Phosphagenics patch eases pain in racehorses
Clinuvel Pharmaceuticals (ASX: CUV) has completed a study using its TPM®/Oxycodone topical patch to manage shin soreness pain for thoroughbred racehorses. READ MORE…
Immuron to sell Travelan® in South Korea
Immuron Limited (ASX: IMC), manufacturer of Travelan®, has entered into an agreement with DB Pharm Korea for the sale of Travelan® in South Korea. READ MORE…
PharmAust gets approval for clinical study
PharmAust Limited (ASX: PAA) has received approval from the Royal Adelaide Hospital Governance Committee to begin evaluation of proprietary drug PPL-1 in a Phase I/II clinical trial in man. READ MORE…
Uscom appoints three new UK distributors
Uscom Limited (ASX: UCM) has appointed three new specialist distributors of the company’s Uscom BP+ suprasystolic oscillometric blood pressure monitor in the United Kingdom. READ MORE…